Meta Information
ID:tirzepatide
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-21T22:30:00Z
Model
phase-a-upgrade-claude-sonnet-4.6
Interactions
Target id:
/class/antidiabetic-medications
Target name:
Insulin or Insulin Secretagogues (e.g., Sulfonylureas)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Tirzepatide lowers blood glucose and has an additive effect with other glucose-lowering medications, significantly increasing the risk of severe hypoglycemia.
Actionable advice:
A dose reduction of concomitant insulin or sulfonylurea may be required; monitor blood glucose frequently.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Exact phrase from label:
Concomitant use with an insulin secretagogue or insulin
Label source:
FDA label: Tirzepatide (Mounjaro)
Action type:
adjust_with_prescriber
Target id:
/class/glp-1-receptor-agonists
Target name:
Other GLP-1 Receptor Agonists (e.g., Semaglutide)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Combining Tirzepatide with other GLP-1 receptor agonists is duplicative therapy, offers no additional benefit, and significantly increases the risk of gastrointestinal side effects.
Actionable advice:
Tirzepatide should not be used in combination with any other GLP-1 receptor agonist.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tirzepatide is a GIP receptor and GLP-1 receptor agonist.
Label source:
Action type:
avoid
Target id:
/condition/medullary-thyroid-carcinoma-history
Target name:
Personal or Family History of Medullary Thyroid Carcinoma (MTC)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
In animal studies, Tirzepatide caused thyroid C-cell tumors. Due to this potential risk, it is contraindicated in individuals with a personal or family history of MTC.
Actionable advice:
This should be strictly avoided if a personal or family history of Medullary Thyroid Carcinoma is present.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 ( 4 ) Known serious hypersensitivity to tirzepatide or any of the excipients in ZEPBOUND ( 4 )
5 WARNINGS AND PRECAUTIONS Severe Gastrointestinal Adverse Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe.
Label source:
Action type:
avoid
Target id:
/condition/men-2-syndrome
Target name:
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Patients with MEN 2 are at high risk for Medullary Thyroid Carcinoma (MTC), making Tirzepatide contraindicated due to the potential risk of thyroid C-cell tumors.
Actionable advice:
This should be strictly avoided in the presence of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined ( 5.1 , 13.1 ).
Label source:
Action type:
avoid
Target id:
/class/estrogens
Target name:
Oral Hormonal Contraceptives
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Tirzepatide delays gastric emptying, which can reduce the absorption and effectiveness of oral hormonal contraceptives, increasing the risk of unintended pregnancy.
Actionable advice:
A non-oral contraceptive should be used, or a barrier method added, for 4 weeks after starting and for 4 weeks after each dose increase.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Following administration of a combined oral contraceptive (0.035 mg ethinyl estradiol and 0.25 mg norgestimate) in the presence of a single dose of tirzepatide 5 mg, mean C max of ethinyl estradiol, norgestimate, and norelgestromin was reduced by 59%, 66%, and 55%, while mean AUC was reduced by 20%, 21%, and 23%, respectively.
Label source:
Action type:
adjust_with_prescriber
Target id:
/procedure/surgery-anesthesia
Target name:
Surgery with General Anesthesia
Severity:
major
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
168
Hours after target:
null
Description:
The delay in gastric emptying caused by Tirzepatide increases the risk of vomiting and aspiration of stomach contents during anesthesia.
Actionable advice:
Tirzepatide should be discontinued at least 1 week prior to elective surgeries requiring general anesthesia.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
5.9 Pulmonary Aspiration During General Anesthesia or Deep Sedation ZEPBOUND delays gastric emptying [see Clinical Pharmacology ( 12.2 )] .
Label source:
Action type:
avoid
Target id:
/condition/history-of-pancreatitis
Target name:
History of Pancreatitis
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
GLP-1 receptor agonists have been associated with acute pancreatitis; it is unknown if the risk is higher in those with a prior history, so caution is warranted.
Actionable advice:
This should be used with caution and discontinued immediately if severe abdominal pain suggestive of pancreatitis develops.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Exact phrase from label:
Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients
Label source:
FDA label: Tirzepatide (Mounjaro)
Action type:
avoid
Target id:
/condition/severe-gi-disease
Target name:
Severe Gastrointestinal Disease (e.g., Gastroparesis)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Tirzepatide slows gastric emptying and has not been studied in patients with severe GI disease; it is likely to worsen symptoms.
Actionable advice:
Use should be avoided with severe gastroparesis or other significant gastrointestinal motility disorders.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
Severe Gastrointestinal Adverse Reactions
Label source:
FDA label: Tirzepatide (Zepbound) — Section 5.2
Action type:
avoid
Target id:
/intervention/resistance-training
Target name:
Resistance Training
Severity:
major
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Weight loss induced by Tirzepatide involves both fat and lean mass. Resistance training is essential to stimulate muscle protein synthesis and preserve muscle mass and strength.
Actionable advice:
Incorporate a consistent resistance training program (at least 2-3 times per week) to mitigate muscle loss.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
Preservation of lean soft tissue during weight loss
Label source:
Primary literature: Prentice E et al., SAGE Open Med Case Rep 2025 — Preservation of lean soft tissue during GLP-1-induced weight loss with resistance training
Action type:
informational_none
Target id:
/intervention/protein
Target name:
Adequate Protein Intake
Severity:
major
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The appetite suppression and caloric deficit from Tirzepatide can lead to significant muscle loss if dietary protein is insufficient to meet the body's needs.
Actionable advice:
Consume adequate daily protein (e.g., 1.2-1.6 g/kg of ideal body weight) to support muscle preservation.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
Tirzepatide lowers fasting and postprandial glucose concentration, decreases food intake, and reduces body weight in
Label source:
FDA label: Tirzepatide (MOUNJARO) — Section 12.1 Mechanism of Action (supports protein-intake guidance to preserve lean mass during weight reduction)
Action type:
informational_none
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Based on animal reproduction studies, there may be risks to the fetus from exposure to Tirzepatide during pregnancy. It is not recommended for use.
Actionable advice:
Use should be discontinued at least 2 months before a planned pregnancy and should be avoided completely during pregnancy.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy.
Label source:
Action type:
avoid
Target id:
/class/oral-medications-general
Target name:
All Oral Medications
Severity:
moderate
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Tirzepatide delays gastric emptying, which can slow the absorption rate and potentially reduce the total amount absorbed of any co-administered oral medication.
Actionable advice:
It is worth being aware that the onset of action for other oral medications may be delayed; it is a good idea to monitor their effects closely.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
7 DRUG INTERACTIONS ZEPBOUND delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications.
Label source:
Action type:
monitor
Target id:
/class/narrow-therapeutic-index-drugs
Target name:
Narrow Therapeutic Index Drugs (e.g., Warfarin, Digoxin)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Delayed gastric emptying can alter the absorption profile of oral drugs with a narrow therapeutic index, potentially leading to sub-therapeutic or toxic levels.
Actionable advice:
Drug levels and clinical effect (e.g., INR for warfarin) should be monitored closely when starting or adjusting Tirzepatide.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with ZEPBOUND.
Label source:
Action type:
monitor
Target id:
/condition/diabetic-retinopathy
Target name:
Diabetic Retinopathy
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
In patients with a history of diabetic retinopathy, rapid improvements in glycemic control have been associated with a temporary worsening of the condition.
Actionable advice:
It is worth watching out for any changes in vision or progression of diabetic retinopathy after starting treatment.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
5.8 Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Mellitus Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy.
Label source:
Action type:
monitor
Target id:
/condition/renal-impairment
Target name:
Renal Impairment
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Gastrointestinal side effects like vomiting or diarrhea can cause dehydration, which may lead to acute kidney injury or worsen underlying kidney disease.
Actionable advice:
Adequate hydration is best maintained, and renal function is best monitored, especially if severe GI side effects occur.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
( 5.2 ) Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion.
Label source:
Action type:
monitor
Target id:
/dietary/alcohol-acute
Target name:
Alcohol (Acute Consumption)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Alcohol can independently lower blood sugar, increasing the risk of hypoglycemia when combined with Tirzepatide. It may also irritate the stomach and increase pancreatitis risk.
Actionable advice:
Alcohol consumption is best limited, and blood glucose levels are best monitored carefully if drinking.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Exact phrase from label:
Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia.
Label source:
FDA label: Tirzepatide (MOUNJARO) — Section 5.3 Hypoglycemia (alcohol independently lowers blood glucose, supporting cautionary advice)
Action type:
monitor
Target id:
/class/glucose-lowering-supplements
Target name:
Glucose-Lowering Supplements (e.g., Berberine)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Supplements known to lower blood sugar (such as berberine, cinnamon, or alpha-lipoic acid) can have an additive effect with Tirzepatide, increasing hypoglycemia risk.
Actionable advice:
Caution is warranted, and blood glucose should be monitored closely, when combining with supplements that affect blood sugar.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Exact phrase from label:
Concomitant use with an insulin secretagogue or insulin
Label source:
FDA label: Tirzepatide (Mounjaro)
Action type:
monitor
Target id:
/class/dpp4-inhibitors
Target name:
DPP-4 Inhibitors (e.g., Sitagliptin)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The combination has not been studied and is not recommended, as both drug classes work by increasing incretin hormone levels, leading to overlapping mechanisms.
Actionable advice:
Tirzepatide is best avoided in combination with a DPP-4 inhibitor.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Exact phrase from label:
MOUNJARO® (tirzepatide) Injection, for subcutaneous use
Label source:
FDA label: Tirzepatide (Mounjaro)
Action type:
avoid
Target id:
/dietary/water
Target name:
Adequate Water/Fluid Intake
Severity:
moderate
Interaction type:
requirement
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Common gastrointestinal side effects like nausea, vomiting, or diarrhea can increase the risk of dehydration, which can lead to acute kidney injury.
Actionable advice:
Consistent and adequate fluid intake throughout the day is a good idea to maintain proper hydration.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The majority of the reported events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions ( 6.1 )] .
Label source:
Action type:
informational_none
Target id:
/biomarker/dexa-scan
Target name:
DEXA Scan for Body Composition
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Periodic DEXA scans provide crucial data on changes in fat mass, lean mass, and bone density, enabling adjustments to diet and exercise to optimize health outcomes.
Actionable advice:
Obtain a baseline DEXA scan before starting and monitor body composition every 3-6 months during treatment.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
Glucagon-like peptide-1 receptor agonists and muscle
Label source:
Primary literature: Pharmacological Research 2025 — GLP-1 receptor agonists and muscle mass review (supports body-composition monitoring during GLP-1 therapy)
Action type:
monitor
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
It is unknown whether Tirzepatide is present in human milk or its effects on a breastfed infant. A decision should be made to discontinue breastfeeding or the drug.
Actionable advice:
It is important to talk to a doctor about the risks and benefits to decide whether to use this medication while breastfeeding.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ZEPBOUND and any potential adverse effects on the breastfed infant from ZEPBOUND or from the underlying maternal condition.
Label source:
Action type:
informational_none
Target id:
/intervention/acetaminophen
Target name:
Acetaminophen (Paracetamol)
Severity:
minor
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Tirzepatide's delay of gastric emptying slows the absorption of acetaminophen, which can delay its onset of action for pain or fever relief.
Actionable advice:
The time to pain relief from oral acetaminophen may be longer than usual.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
After coadministration at Week 6 with tirzepatide 15 mg, there was no meaningful impact on acetaminophen C max and t max .
Label source:
Action type:
informational_none